Peptide Conjugated Lipid Nanoparticles and Cancer Drug Delivery
Keywords:
Peptide-conjugated lipid nanoparticles,, nanotechnology, angiogenesis, anti-angiogenesis, lung cancer, breast cancerAbstract
Peptide Conjugated Lipid Nanoparticles and their role on Cancer Drug Delivery are reviewed here. The benefits of nanotechnology and combination style of medicine delivery are still hindered without the active ligands needed for treatment efficacy. This work analyzes the role of peptide ligands in different forms of cancer treatments targeting cells and tissues.
Downloads
Downloads
Published
30-11-2018
Issue
Section
Review Articles
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
How to Cite
1.
Xiao W. Peptide Conjugated Lipid Nanoparticles and Cancer Drug Delivery. Int J of Adv in Sci Res [Internet]. 2018 Nov. 30 [cited 2025 Jul. 21];4(11):95-7. Available from: https://ssjournals.co.in/index.php/ijasr/article/view/4960
